223 related articles for article (PubMed ID: 26942600)
1. Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
Fukami S; Riemenschneider MJ; Kohno M; Steiger HJ
Brain Tumor Pathol; 2016 Jul; 33(3):191-9. PubMed ID: 26942600
[TBL] [Abstract][Full Text] [Related]
2. High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression.
Esen H; Feyzioglu B; Erdi F; Keskin F; Kaya B; Demir LS
Brain Tumor Pathol; 2015 Jul; 32(3):195-201. PubMed ID: 25592259
[TBL] [Abstract][Full Text] [Related]
3. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
4. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P
Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215
[TBL] [Abstract][Full Text] [Related]
5. p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade.
Nozaki M; Tada M; Kashiwazaki H; Hamou MF; Diserens AC; Shinohe Y; Sawamura Y; Iwasaki Y; de Tribolet N; Hegi ME
Brain Pathol; 2001 Jul; 11(3):296-305. PubMed ID: 11414472
[TBL] [Abstract][Full Text] [Related]
6. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings.
Al-Mefty O; Kadri PA; Pravdenkova S; Sawyer JR; Stangeby C; Husain M
J Neurosurg; 2004 Aug; 101(2):210-8. PubMed ID: 15309910
[TBL] [Abstract][Full Text] [Related]
7. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
[TBL] [Abstract][Full Text] [Related]
9. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma.
Paramasivam N; Hübschmann D; Toprak UH; Ishaque N; Neidert M; Schrimpf D; Stichel D; Reuss D; Sievers P; Reinhardt A; Wefers AK; Jones DTW; Gu Z; Werner J; Uhrig S; Wirsching HG; Schick M; Bewerunge-Hudler M; Beck K; Brehmer S; Urbschat S; Seiz-Rosenhagen M; Hänggi D; Herold-Mende C; Ketter R; Eils R; Ram Z; Pfister SM; Wick W; Weller M; Grossmann R; von Deimling A; Schlesner M; Sahm F
Acta Neuropathol; 2019 Aug; 138(2):295-308. PubMed ID: 31069492
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
Goutagny S; Yang HW; Zucman-Rossi J; Chan J; Dreyfuss JM; Park PJ; Black PM; Giovannini M; Carroll RS; Kalamarides M
Clin Cancer Res; 2010 Aug; 16(16):4155-64. PubMed ID: 20682713
[TBL] [Abstract][Full Text] [Related]
11. Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression.
Pećina-Šlaus N; Kafka A; Vladušić T; Tomas D; Logara M; Skoko J; Hrašćan R
Int J Exp Pathol; 2016 Apr; 97(2):159-69. PubMed ID: 27292269
[TBL] [Abstract][Full Text] [Related]
12. Meningiomas: analysis of loss of heterozygosity on chromosome 10 in tumor progression and the delineation of four regions of chromosomal deletion in common with other cancers.
Mihaila D; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4435-42. PubMed ID: 14555516
[TBL] [Abstract][Full Text] [Related]
13. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Zhang M; Xu E; Zhang J; Chen X
Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
[TBL] [Abstract][Full Text] [Related]
14. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
[TBL] [Abstract][Full Text] [Related]
15. Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas.
Cho H; Ha SY; Park SH; Park K; Chae YS
J Korean Med Sci; 1999 Apr; 14(2):199-205. PubMed ID: 10331568
[TBL] [Abstract][Full Text] [Related]
16. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
17. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
18. BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region.
Wozniak K; Piaskowski S; Gresner SM; Golanska E; Bieniek E; Bigoszewska K; Sikorska B; Szybka M; Kulczycka-Wojdala D; Zakrzewska M; Zawlik I; Papierz W; Stawski R; Jaskolski DJ; Och W; Sieruta M; Liberski PP; Rieske P
Cancer Genet Cytogenet; 2008 May; 183(1):14-20. PubMed ID: 18474292
[TBL] [Abstract][Full Text] [Related]
19. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
Bie L; Zhao G; Ju Y; Zhang B
Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
[TBL] [Abstract][Full Text] [Related]
20. Microarray Expression Data Identify DCC as a Candidate Gene for Early Meningioma Progression.
Schulten HJ; Hussein D; Al-Adwani F; Karim S; Al-Maghrabi J; Al-Sharif M; Jamal A; Al-Ghamdi F; Baeesa SS; Bangash M; Chaudhary A; Al-Qahtani M
PLoS One; 2016; 11(4):e0153681. PubMed ID: 27096627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
